

YONG TAI BERHAD
Registration No. 199401025505 (311186-T)
(Incorporated in Malaysia)

SUMMARY OF QUESTIONS RAISED BY THE SHAREHOLDERS AND THE COMPANY'S RESPONSES AT THE EXTRAORDINARY GENERAL MEETING HELD FULLY VIRTUAL VIA AN ONLINE MEETING PLATFORM ON WEDNESDAY, 22 DECEMBER 2021 AT 10.30 A.M.

Question 1

The shares dilution will occur for this corporate action?

Answer 1

The question no. 1 was answered by Mr Lee Beng Yew, the Principal Advisers from Kenanga Bank Berhad. Based on item 6.3 of the Circular to Shareholders dated 30 November 2021, it was mentioned that the conversion of the RCPS will result in dilution to the earning or loss per Share of the Group due to the increased number of issued Shares of the Company.

Question 2

What's the implication on the vaccine business?

Answer 2

Question no. 2 was answered by Datuk Wira Boo Kuang Loon. Currently the compilation of interim data from clinical trial is on-going. However due to the acceleration of the national immunisation programme in Malaysia, the available data to conclude the efficacy, safety and immunogenicity of the vaccine is limited. Hence, the Company will have to rely on the interim trial results conducted by its strategic partner, Shenzhen Kangtai in other countries such as Philippines and Ukraine in order to submit to NPRA for the conditional registration approval of the vaccine in Malaysia.

Question 3

Considering the recent approval given to Covid antibodies drugs (mAbs) by China and US.

Answer 3

Question no. 3 was answered by Datuk Wira Boo Kuang Loon. As per medical experts' opinion, the best way to fight with the virus is through vaccination. Moreover, the Covid antibodies drugs is still in trial stage.